In non-small cell lung cancer, CCL19 and CXCL11 reduced the receptor activator of nuclear factor-κB ligand/osteoprotegerin ratio, an indicator of osteoclast stimulation (Kim et al., 2015). Here, CCL19 is linked to non-small cell lung carcinoma.